Oncology trials are considered to be more complicated than trials in any other therapeutic area. The research in oncology differs in the trial design, type of trial, the role of a comparator, treatment outcomes, adverse events reporting, interpreting the results, etc.
The growth in the global oncology market is moving at a rapid pace. In 2017, the oncology drug market was valued at $97,400 million and was estimated to reach $ 176,509 million by 2025, registering a CAGR of 7.6%. Similarly, the research and the number of clinical trials have been increased in folds.
Despite this rapid growth, there are several hiccups. For example, a study reports that only 5.1% of new cancer drugs tested in Phase I are likely to receive FDA approval. The success rate of trials reaching from Phase-I to Phase II is 63%, and 25% from reaching Phase-II to Phase III.
Before moving into the challenges and strategies to overcome, let’s look at the statistics of clinical trials conducted worldwide.
Clinical trial statistics in Oncology
Currently, a total of 77,626 trials are registered in oncology on clinicaltrials.gov all over the world with 22,352 ongoing trials.
The major number of trials are being registered in the USA (11,424), Europe (6,640), and China (3,355).
Improvements in oncology research
Along with the Increasing statistics, there are markable improvements in the oncology research industry
- The 15 therapeutic drugs were approved and launched in 19.
- More than half of the approved treatments were from the oral route.
- Most of the treatments bought were being applicable for varying cancer populations and in earlier lines of therapies.
- The research in immuno-oncology trials has increased.
- As per a source, In the past five years, 57 newly discovered drugs received approval for 89 indications.
- In 2019, 11 oncology drugs received FDA approvals.
- Seven of these approvals were for the drugs used in the treatment of solid tumors, and four were the drugs used to treat hematologic malignancies.
Besides these improvements, the clinical trials in oncology present a few challenges that need to be overcome. Here are the top challenges in oncology
Top 7 challenges in oncology clinical trials
- Lack of well-defined strategies
- Selection of an ideal study designs
- Regulatory hurdles
- Identifying perfect sites and investigators
- Patient recruitment and retention
- Lack of predefined study end-points
- Significant costs involved in oncology clinical trials
Clinical development strategy in oncology trials
Developing a perfect clinical development strategy for clinical trials in oncology is crucial as the research involves significant costs, time, and challenges. So creating a well-defined path reduces the hurdles, avoids delays and costs that incur due to delays.
A clinical development strategy is a clear, structured path designed right from the late pre-clinical stage to phase-III studies. An ideal clinical development strategy defines every step in development, foresees the hurdles that may arise through applying scientific knowledge from the expertise.
Let’s see the challenges in oncology trials and the clinical development strategy to manage those challenges briefly.
Before even planning a clinical trial, it’s obvious to find the country you need to conduct your clinical trials. The country you choose impacts your clinical trials in many ways, such as
- Regulatory scenario and approval timelines
- Patient population available for recruitment and clinical trial awareness
- Cost per site or cost per a study in that particular region
- Data acceptance with other regulators
- Number of sites and site reachability
- Logistics and supply chains
- Language barriers and other considerations
Along with these factors, there are many more considerations to make a note of while choosing a region.
When unsure about the region, it’s wise to conduct country-level clinical trial feasibility to answer all these questions, which may help to move optimistically forward by foreseeing the hurdles that may arise during the trial conduction.
Considering the regulatory is another aspect of clinical development strategy.
- Some of the regulators offer special considerations in the designs. For example, the FDA recommends using adaptive designs such as Basket trial designs, Platform trial designs, and Umbrella trial designs.
- Regulators like FDA, EMA offer fast track approvals and priority approval for a selected class of drug research, which fastens the development process.
- Regulators provide special incentives and benefits for Oncology-rare diseases.
- Some of the regulators accept overseas clinical trial data. It is obvious to go with the regulators of a country where conducting a clinical trial is widely acceptable.
Clinical trial design
Selecting efficient trial designs helps in utilizing minimum resources and yet producing valid quality data. Modern study designs help to evaluate treatment in multiple disease subtypes in a single study.
Patient recruitment is a challenging task in the clinical trial industry, and choosing an adaptive trial design is one solution to avoid trial delays due to recruitment.
Clinical trial sites and Investigators
One of the challenging factors in the clinical trial industry is finding the right sites and investigators. After the study initiation, it is the clinical trial clinical investigator who drives the clinical trial forward, and choosing the most efficient resource minimizes hurdles and avoids delays in the clinical trials.
The key considerations in the selection of sites and investigators include
- Quality sites and investigators
- Study timelines
- Patient recruitment strategies
- Quality data generation
The quality site and investigator selection
A qualified investigator handles the complex trials and helps in producing precise data. Choosing the right investigator and site for oncology trials helps in,
- Understanding & management of complex, adaptive trial designs
- Better patient recruitment and retention rates
- Having the necessary resources and infrastructure to record observations such as MRI, CT Scan, X-Ray, etc.
- Good patient tracking and counseling to extract precise patient data
- GCP adherence
- Maintaining and utilizing the record system, and data storage facilities
- Patient facilitation and hospitality
The study start-up phase at the site level requires a significant administrative and logistical undertaking. The initiation of a new clinical trial typically involves
- Completion of a feasibility questionnaire,
- Budget and contract negotiation
- Institutional Review Board (IRB) preparation and submission,
- Regulatory essential documents collection,
- Establishment of study logistics in collaboration with ancillary services within the institution and
- Development of a patient recruitment strategy
Study initiation delays are generally observed in oncology clinical trials. Creating strategies to shorten the timeline to avoid the extended delays will expedite patient access to novel therapies and improve patient care.
One of the studies shows that the longest timeline is the IRB approval to activation (12 weeks) and this can be strategically minimized by putting the focus on gaining early IRB approvals to decrease the overall activation time by 50%.
Similarly study activation delays were found due to resource recruitment and staffing. The site with sufficient resources reduces these timelines.
Patient recruitment strategies
Patient recruitment is a global impending task for any clinical trial and is more obvious with oncology and rare disease trials. The major tasks in the oncology trials for patient recruitment include
- Multiple disease sub-types (this makes the patient fit into the inclusion and exclusion criteria)
- Similar organ affected with different genes involved
- Patient already receiving treatments (which may affect the current treatment plans)
- Lack of gold standard treatments
- Oncology clinical trials are checked for multiple parameters and concurrent disease conditions for recruitment
- Lack of patients’ interest in receiving new treatments.
- Oncology trials require continuous observations and in-hospital treatments.
For these complications involved in patient recruitment 70-80% of hurdles can be resolved utilizing a proper recruitment strategy. Here are some of them
- Utilizing patient organization database to contact and recruit.
- Broadening inclusion and exclusion criteria.
- Utilizing adaptive trial designs where treatment can be explored in multiple disease scenarios.
- Choosing sites and investigators considering patient visits, and patient recruitment capabilities.
- Site reachability to patient populations. (remote sites have difficulties in recruitment).
- Site facilities.
Quality data generation
Data quality and integrity are the cornerstones of all clinical trials. Clinical trials in oncology are unique due to their toxicity monitoring, endpoint assessment, and follow-up.
Here are some of the tips included in the clinical development strategy that helps to improve the quality of generated
- Ensure to review the guidance documents provided by various regulators to ensure the compliance
- Fit for purpose methodologies implies that data quality improves when the data collected becomes more targeted to the study objectives and eliminating non-critical data points during endpoint analysis.
- Clearly define critical data points and standardize their collection and monitoring processes.
- Identify critical data points
- Establish detailed standard operating procedures (SOPs)
- Identifying the best system for your operational needs such as EDC/eCRF systems
Real-world data evidence (RWE)
Real-World Data (RWD) are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources. Real-World Evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a medical product derived from the analysis of RWD.
Are you looking for support in drug development for Oncology?
Talk to us today. Provide details of your requirements and we will connect with you.